enGene Therapeutics Inc. (ENGN)

NASDAQ: ENGN · Real-Time Price · USD

7.76

+0.16 (2.11%)

Apr 15, 2026, 4:00 PM EDT - Market closed

enGene Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 15, 2026	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Market Capitalization	520	369	451	343	160	-
Market Cap Growth	127.62%	-18.18%	31.50%	113.74%	-	-
Enterprise Value	277	199	218	438	-	-
Last Close Price	7.76	7.21	8.85	21.70	10.15	-
PB Ratio	1.85	2.20	1.66	4.73	-13.33	-
P/TBV Ratio	1.85	2.20	1.66	4.73	-	-
Debt / Equity Ratio	0.12	0.19	0.09	0.14	-2.35	0.41
Net Debt / Equity Ratio	-0.86	-0.97	-0.78	-0.99	-0.65	-0.85
Net Debt / EBITDA Ratio	1.91	1.32	3.44	2.77	-0.41	0.48
Net Debt / FCF Ratio	2.34	1.61	4.34	2.86	-0.44	0.46
Quick Ratio	11.36	6.13	16.33	15.95	4.26	3.93
Current Ratio	11.75	6.30	16.87	16.25	4.43	4.20
Return on Equity (ROE)	-46.07%	-53.28%	-31.96%	-330.60%	-	-
Return on Assets (ROA)	-25.63%	-28.90%	-19.56%	-29.38%	-62.37%	-
Return on Capital Employed (ROCE)	-40.90%	-65.00%	-21.00%	-31.90%	-103.30%	-134.40%
Earnings Yield	-23.55%	-31.78%	-12.22%	-29.13%	-15.24%	-
FCF Yield	-19.96%	-27.29%	-10.91%	-7.31%	-11.06%	-
Buyback Yield / Dilution	-23.39%	-35.30%	-5355.08%	-5.72%	81.61%	-28.93%

Updated Mar 9, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q